Market Overview

UPDATE: Citigroup Raises Eli Lilly PT to $60 on Eli Lilly on Potential Upside

Share:
Related LLY
Benzinga's Top Initiations
U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent
Eli Lilly's (LLY) Diabetes Drug Synjardy Gets U.S. Approval (Zacks)

Citigroup maintained Eli Lilly and Company (NYSE: LLY) with a Buy rating and raised the price target from $55.00 to $60.00.

Citigroup noted, "Lilly's base business is performing ahead of our expectations (Alimta, Elanco, Diabetes and Emerging markets). Consequently, we continue to see upside for Lilly due to the asymmetric risk reward given the minimal value being discounted for the key pipeline agent ramucirumab (cancer). Buy-rated Pfizer, Lilly and Forest remain our favoured names in US pharma."

Eli Lilly closed at $54.32 on Tuesday.

Latest Ratings for LLY

DateFirmActionFromTo
Aug 2015BerenbergInitiates Coverage onBuy
Aug 2015JefferiesMaintainsBuy
Jul 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

Get Benzinga's Newsletters